Oncology & Cancer

Sorafenib effect on HCC survival depends on hepatitis status

(HealthDay)—For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients' hepatitis status, according to a meta-analysis published online Jan. ...

Oncology & Cancer

Novel combination therapy shows strong response in phase 1 trial

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. ...

Oncology & Cancer

Widely used kidney cancer drugs can't stop recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life ...

Oncology & Cancer

Sorafenib modestly increases progression-free survival

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), ...

page 1 from 4